Anticholinesterases Flashcards
MOA of anticholinesterases
Blocks hydrolytic inactivation of ACh in synapse to enhance and prolong stimulation of cholinergic receptors
Anticholinesterase sites of action
ANS- muscarinic, nicotinic, and NMJ nicotinic receptors
CNS- cholinergic neurons (especially for cognition)
Anticholinesterases cause _____ paralysis
Flaccid
Reversible (non-covalent) anticholinesterase
Donepezil
Donepezil can/can’t cross BBB
Can
Donepezil clinical use
Treatment of Alzheimer’s
Donepezil Alzheimer’s MOA
Deficiency of cerebral ACh counteracted by central inhibition of ACh degradation
Doesn’t affect disease progression
Donepezil adverse effects
Diarrhea
N/V
Bradycardia
Prototype reversible covalent anticholinesterase
Neostigmine
Low (therapeutic) doses of neostigmine increase/decrease contractile force
Increase
High (toxic) doses of neostigmine increase/decrease contractile force
Decrease (N receptor desensitization)
Neostigmine MOA
Direct agonist at Nm receptors; induce muscle contraction without ACh release
Duration of neostigmine action
2 hours
Circulating neostigmine is cleared by ____
Butylcholinesterase
Neostigmine does/doesn’t cross the BBB
Doesn’t